RnDCircle Logo
박영준 연구실
제주대학교 약학과
박영준 교수
기본 정보
연구 분야
프로젝트
발행물
구성원

박영준 연구실

제주대학교 약학과 박영준 교수

박영준 연구실은 제주대학교 약학과를 기반으로 세포면역과 종양면역을 중심으로 한 기전 연구를 수행하며, 특히 종양미세환경에서의 조절 T세포 기능, 면역억제 기전, Th17 세포 및 기타 면역세포의 병적 전환을 규명하고 이를 바탕으로 면역항암 및 염증질환 치료 표적을 발굴하는 데 주력하고 있다. 또한 아열대 천연물과 청정 바이오소재를 활용한 치료 후보물질 탐색 및 바이오헬스 응용 연구를 병행하여 기초 면역학과 약학적 실용화를 연결하는 융합 연구를 전개하고 있다.

대표 연구 분야
연구 영역 전체보기
종양면역과 조절 T세포 제어 thumbnail
종양면역과 조절 T세포 제어
주요 논문
3
논문 전체보기
1
article
|
인용수 0
·
2023
Abstract 18249: Artificial Intelligence-Based Electrocardiogram Prediction for Duration of Atrial Fibrillation
Young Jun Park, Kyung Geun Kim, Sunghoon Joo, Mineok Chang, Yeha Lee
IF 38.6
Circulation
Introduction: Atrial fibrillation (AF) is the most common sustained arrhythmia and is associated with poor clinical outcomes, including stroke, acute coronary events, and heart failure. Recent studies have shown that early rhythm treatment of new-onset atrial fibrillation improves the patient's prognosis. However, atrial fibrillation is often asymptomatic, and it is difficult to determine its duration accurately. Recently, AI-based ECG has been studied for various cardiovascular diseases. Hypothesis: We sought to develop and validate a predictive model of the ECG for the duration of atrial fibrillation . Methods: All patients aged 18 years older from the two hospitals with at least one ECG were included in the study. Only patients with sinus rhythm with ECG prior to atrial fibrillation with ECG were selected. An ECG within 1 year from AF was first documented in ECG was defined as new onset AF. After dividing our datasets into training (and test sets, we developed an end-to-end deep neural network to predict for the duration of AF. Performance evaluation was conducted using various metrics, including AUROC, AUPRC, sensitivity, specificity, F1 score. Results: The dataset consisted of 83,525 ECGs from 16,193 patients from two hospitals. The AUROC for discriminating old AF and new-onset AF is 0.8186 (0.8181 - 0.8190) on internal validation set and 0.7967 (0.7966 - 0.7969) on external validation set. Sensitivity, Specificity, and F1 score are 0.7126((0.7118-0.7134), 0.7697 (0.7693-0.7701) and 0.5751 (0.5745-0.5757) on internal validation set and 0.7309 (0.7307-0.7311), 0.7225 (0.7224-0.7227) and 0.6354 (0.6352-0.6356)on external validation set. Conclusions: Our deep learning model can be used to predict atrial fibrillation's duration. Additional studies are ongoing to understand the relative importance of ECG features.
http://dx.doi.org/10.1161/circ.148.suppl_1.18249
Medicine
Atrial fibrillation
Internal medicine
Cardiology
Sinus rhythm
Asymptomatic
Stroke (engine)
Heart failure
2
article
|
인용수 0
·
2023
Abstract 14208: New Artificial Intelligence Algorithms of Electrocardiogram Detection for Patients With Heart Failure
Young Jun Park, Kyung Geun Kim, Sunghoon Joo, Mineok Chang, Yeha Lee
IF 38.6
Circulation
Introduction: Heart failure (HF) is a global pandemic with an increasing prevalence. The burden of HF-related hospitalizations and costs are increasing. Artificial intelligence(AI) algorithms applied to electrocardiograms have shown promise in diagnosing HF, but they require a large amount of training data, which is scarce and costly. Transfer learning addresses this challenge by utilizing knowledge from previous tasks, resulting in superior performance with limited data compared to conventional AI algorithms Hypothesis: AI algorithms using transfer learning can be accurately diagnose heart failure with reduced ejection fraction(HFrEF) using electrocardiograms compared to conventional AI algorithms. Methods: All patients aged 18 years older from the two hospitals with at least one ECG were included in the study. Electrocardiogram, transthoracic Echocardiogram (TTE), and demographic data were collected. The AI algorithm consisted of two phases: conventional AI algorithms, pre-training with a large-scale ECG dataset and transfer learning for HFrEF detection. Performance evaluation was conducted using various metrics, including AUROC, sensitivity, specificity, accuracy, F1 score. Results: The dataset consisted of 687,911 ECGs from 259,943 patients. Testing the conventional model on the HFrEF resulted in a sensitivity of 63.8%, specificity of 96.2%, accuracy of 93.6%, area under the receiver operating curve (AUC) of 0.93 (95% CI, 0.92 - 0.94), and F1 score of 61.6%. Testing the transfer learning model on the HFrEF increased the sensitivity of 75.1%, accuracy of 93.7%, area under the receiver operating curve (AUC) of 0.952 (95% CI, 0.93 - 0.96), and F1 score of 65.6%. but lowered the specificity of 95.3% Conclusions: A New AI-enabled ECG algorithm for identifying patients with HFrEF can be more accurately diagnosed than conventional AL algorithms.
http://dx.doi.org/10.1161/circ.148.suppl_1.14208
Medicine
Receiver operating characteristic
Ejection fraction
Heart failure
Machine learning
Algorithm
Artificial intelligence
Area under the curve
Transfer of learning
Internal medicine
3
article
|
인용수 0
·
2022
Abstract 12393: Two-Year Clinical Outcome of Mid-Range Ejection Fraction at Admission in Patients With Acute Myocardial Infarction
Ho Sung Jeon, Young In Kim, Junghee Lee, Dong‐Hyuk Cho, Young Jun Park, Jung‐Woo Son, Jun‐Won Lee, Young Jin Youn, Sung Gyun Ahn, Min‐Soo Ahn, Jang‐Young Kim, Byung‐Su Yoo, Seung‐Hwan Lee, Junghan Yoon, Dae Ryong Kang
IF 38.6
Circulation
Introduction: The American Heart Association and European Society of cardiology guidelines reclassified heart failure according to left ventricular ejection fraction, recognizing patients with mid-range EF (mrEF; 40% to 49%) as a distinct group. However, studies on the clinical characteristics of mid-range EF patients and the occurrence of cardiovascular events in acute MI patients are insufficient. Methods: We categorized 6,553 patients with acute myocardial infarction (AMI) from the Korea AMI-National Institutes of Health between November 2011 and December 2015 into three groups (reduced EF ; LVEF < 40% at admission, mild-reduced EF ; LVEF 40 to 49%, preserved EF ;LVEF ≥50%). The primary endpoint was defined as any death at two-year. Secondary endpoints were defined as any myocardial infarction, any revascularization, patient-oriented composite outcome(POCE). Results: Compared to patients with other two groups, the reduced EF group had a highest overall mortality, POCE, and any MI (24.7% vs 8.3% vs 4.6%, p < 0.0001, 33.0% vs 15.6% vs 12.4%, p<0.0001, 3.9% vs 2.7% vs 2.6%, p<0.0046). When mid-range EF group was designated as a reference, in multivariate analysis including all variables, significant differences with HFrEF group was found. (Hazard ratio ). When compared with HFpEF, only Model 1 and Model 2 showed a significant statistical difference (Model 1 ; 0.65 (0.53-0.81), Model 2 ; 0.56 (0.56-0.86). Conclusions: Followed up for two years, significant differences in survival rates were observed between the mid-range EF, reduced EF, and preserved EF group. After adjusting for common prognostic factors affecting the overall mortality rate, the reduced EF group had a significantly higher mortality rate than mid-range EF group, but no significant difference was observed between the preserved EF and the mid-range EF group.
http://dx.doi.org/10.1161/circ.146.suppl_1.12393
Medicine
Ejection fraction
Internal medicine
Myocardial infarction
Cardiology
Hazard ratio
Heart failure
Revascularization
Clinical endpoint
Proportional hazards model
정부 과제
10
과제 전체보기
1
2024년 3월-2029년 3월
|243,557,000
산성 신호 해독을 통한 종양 조절 T세포 제어
-종양의 산성 환경은 면역억제의 주요 원인이지만 그 기전이 모호함. 본 연구에서는 Treg의 면역억제 표현형과 산성 신호(H+) 간의 상관관계를 규명하고 종양 Treg 특이적 표적을 발굴함으로써 새로운 패러다임의 면역 항암치료제 개발을 위한 과학적 근거를 제시하고자 함.
조절 T세포
종양
수소이온
산성
표적 분해제
2
2022년 3월-2024년 12월
|2,760,800,000
청정 바이오소재 코스메틱 기반 고도화 사업
ㅇ 청정바이오소재기반 코스메틱 산업육성을 위한 제품개발, 생산, 평가장비 구축 및 One-Stop서비스 지원 - 플랫폼구축 1건, GMP공장 리모델링 1건, 네트워크 활동 35건 - 장비구축: 15건, 기술지원: 184건, 인력양성: 196명
천연바이오소재
기능성화장품
코스메슈티컬
효능평가
안전성평가
3
주관|
2022년 3월-2024년 12월
|2,241,400,000
청정 바이오소재 코스메틱 기반 고도화 사업
본 과제는 청정바이오소재를 활용한 화장품의 제품개발·생산·평가를 한곳에서 돕는 One-Stop서비스 구축 연구임. 플랫폼 구축, GMP공장 리모델링, 장비·기술지원 및 인력양성 수행함. 연구 목표는 TRL1~TRL5 원료개발~시제품 단계 지원과 TRL6~TRL8 성능인증·신뢰성 평가 단계 충족을 위한 화장품산업화 센터 완성에 있음. 핵심 연구 내용은 제형개발, 홍보용 시제품 제작, KOLAS 연계 안전성평가(중금속·미생물), 바이오 소재·원료·제품 지표·유효성분 기술분석, 표시광고 실증(인체 외 시험) 평가 및 기술지도, 스마트공장 고도화를 위한 리노베이션임. 기대 효과는 기술성숙도 기반 기업수요 충족으로 제주 화장품산업 지역혁신 클러스터 완성에 기여함.
천연바이오소재
기능성화장품
코스메슈티컬
효능평가
안전성평가